TP53 and cancer: Collectively, the above data suggest that ET-1R blockade by macitentan impairs YAP/mutp53 transcriptional machinery; thereby representing an emerging anti-cancer therapeutic approach for combinatorial strategies for HG-SOC harboring common p53 mutations to overcome compensatory mechanism of platinum-based therapy escape.